Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented clinical data from a Phase 2 study of ARC-520 and a Phase 1/2 study of ARC-521, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis B virus (HBV) infection, at The International Liver Congress™ 2017 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL).

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM)

Pasadena. CA | Posted on April 20th, 2017

Together, these presentations demonstrate that in human clinical studies, RNAi interference (RNAi) as a mechanism can rapidly and significantly reduce HBV viral antigens. In addition, RNAi appears to synergize with current standard-of-care nucleotide and nucleoside analogues (NUCs) to rapidly lower serum levels of HBV DNA. Arrowhead is currently developing ARO-HBV, a follow-on product candidate that utilizes the company's next generation, proprietary subcutaneously administered delivery vehicle, as a potentially curative therapy for patients with chronic hepatitis B infection.

Bruce Given, M.D., chief operating officer, head of R&D for Arrowhead Pharmaceuticals, said: "Arrowhead's ARC-520 and ARC-521 clinical studies have generated important data that continue to inform and guide the development path of ARO-HBV, our follow-on candidate against chronic HBV. We saw reductions in hepatitis B surface antigen, or HBsAg, of up to 3 logs following multiple doses with ARC-520 in combination with a NUC. HBV DNA was reduced by several logs and became undetectable in many patients. In addition, early data from the ARC-521 study indicate that RNAi therapeutics can be active against HBV gene products derived from both cccDNA and integrated HBV DNA. These data are consistent with findings from a long-term study in chimpanzees that we reported on previously. We view these results as validation for the use of RNAi in HBV, and believe ARO-HBV has the potential to serve as a cornerstone therapy for combinations intended to cure chronic HBV."

Presentation materials can be accessed by visiting the Events section of the Arrowhead website. Additional details including abstracts can be found on the ILC website at https://ilc-congress.eu/ by searching for the following:

Oral Presentation:

Prolonged RNA interference therapy with ARC-520 Injection in treatment naďve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

Presentation Reference: PS-045
Session: Parallel session: Hepatitis B and D: Emerging treatment options
Date and Time: April 20, 2017 at 5:30 PM CET
Authors: Man-Fung Yuen, et al.
Poster Presentation:

A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

Presentation Reference: THU-176
Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
Authors: Edward Gane, et al.
Arrowhead announced on November 29, 2016 that it had discontinued development of ARC-520, ARC-521. The company continues to develop ARO-HBV, which is a follow on investigational RNAi therapeutic against chronic HBV that utilizes the company's next generation, proprietary subcutaneously administered delivery vehicle.

The International Liver Congress is a trademark of the European Association for the Study of the Liver.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Matthew P. Duffy, 212-915-0685

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Nanomedicine

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Announcements

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Events/Classes

Nanomechanics, Inc. to Exhibit at the SEM Conference: Nanoindentation experts will attend and exhibit their instruments at the Conference and Exposition on Experimental and Applied Mechanics in Indianapolis May 25th, 2017

Leti to Demo 1st Wireless UNB Transceiver for ‘Massive Internet of Things’ at RFIC 2017 and IMS 2017: Leti Will also Present Three Papers & Two Workshops on 5G Communications IC Design, from RF to mm-Wave, During IMS 2017 and RFIC 2017 in Hawaii May 24th, 2017

Leti Will Demo World’s-first WVGA 10-µm Pitch GaN Microdisplays for Augmented Reality Video at Display Week in Los Angles: Invited Paper also Will Present Leti’s Success with New Augmented Reality Technology That Reduces Pixel Pitch to Less than 5 Microns May 22nd, 2017

Oxford Instruments Asylum Research and Microscopy and Analysis Present the Webinar: “Video-Rate Atomic Force Microscopy Enables New Research Opportunities” May 9th, 2017

Nanobiotechnology

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Oddball enzyme provides easy path to synthetic biomaterials May 17th, 2017

The brighter side of twisted polymers: Conjugated polymers designed with a twist produce tiny, brightly fluorescent particles with broad applications May 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project